ClinicalTrials.gg

Program

MK4646

A development code. Also written as “MK-4646”.

Its studies are mostly in HIV Infections, led by Merck.

Furthest: phase 1, since Jun 9, 20254 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck41 open or runningphase 1since Jun 9, 2025Jun 9, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2025First study: phase 1 study in HIV InfectionsFirst studyNCT07042945 · 15 enrolled · Moldova, Romania
  2. Sep 22, 2025Phase 1 study in HealthyNCT07199452 · 18 enrolled · United States
  3. Apr 8, 2026Phase 1 study in HealthyNCT07532304 · 16 enrolled · United States
  4. Aug 21, 2026Phase 1 study in HealthyNCT07785830 · 16 enrolled · United States

Ahead

  1. Nov 10, 2026Primary completion: phase 1 study in HealthyNCT07785830

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07785830Healthy · United States1Active, not recruitingNov 10, 202616
NCT07532304Healthy · United States1CompletedJul 23, 202616
NCT07199452Healthy · United States1CompletedDec 27, 202518
NCT07042945HIV Infections · Moldova, Romania1CompletedJun 5, 202615

How it is read

Names in the registry

  • “MK-4646”, 3 entries
  • “MK4646”, 1 entry

Codes read as this program: MK4646.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.